A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab-deruxtecan (Primary) ; Cyclophosphamide; Doxorubicin
Indications Early breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Registrational; Therapeutic Use
Acronyms DESTINY-Breast11
Sponsors AstraZeneca; AstraZeneca AB

Most Recent Events

08 Nov 2024 Planned primary completion date changed from 20 Dec 2024 to 12 Mar 2025.
26 Apr 2024 Status changed from recruiting to active, no longer recruiting.
26 Sep 2023 Planned End Date changed from 26 Jun 2026 to 30 Apr 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight